World Organisation for Animal Health

Nicolas Eterradossi - - FRANCE

WOAH Reference Laboratory Reports Activities 2025

This report has been submitted: 22 janvier 2026 18:45

LABORATORY INFORMATION

***Name of disease (or topic) for which you are a designated WOAH Reference Laboratory:**	Turkey rhinotracheitis
***Address of laboratory:**	Anses - 41 route de Beaucemaine - BP53 - 22440 - Ploufragan - France
***Tel:**	+33 (0)2 96 01 62 22
***E-mail address:**	nicolas.eterradossi@anses.fr
Website:	https://www.anses.fr/fr/content/laboratoire-de-ploufragan-plouzane-niort
***Name (including Title) of Head of Laboratory (Responsible Official):**	Dr Nicolas ETERRADOSSI
***Name (including Title and Position) of WOAH Reference Expert:**	Dr Nicolas ETERRADOSSI, Director
***Which of the following defines your laboratory? Check all that apply:**	Governmental

TOR1: DIAGNOSTIC METHODS

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in WOAH Manual (Yes/No)	Total number of test performed last year	
Indirect diagnostic tests		Nationally	Internationally
ELISA for the detection of AMPV antibodies	Yes	5633	620
Direct diagnostic tests		Nationally	Internationally
Viral isolation and propagation in vero cells	Yes	4	0
Detection and quantification of AMPV genome by rtRT-PCR	Yes	60	0

TOR2: REFERENCE MATERIAL

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by WOAH?

No

3. Did your laboratory supply standard reference reagents (nonWOAH-approved) and/or other diagnostic reagents to WOAH Members?

Yes

Type of reagent available	Related diagnostic test	Produced/ provide	Amount supplied nationally (ml, mg)	Amount supplied internationally (ml, mg)	No. of recipient WOAH Member Countries	Country of recipients
Antigen	ELISA	Produced and provided	20 ml	0	1	FRANCE,

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to WOAH Members?

TOR3: NEW PROCEDURES

6. Did your laboratory develop new diagnostic methods for the designated pathogen or disease?

No

7. Did your laboratory validate diagnostic methods according to WOAH Standards for the designated pathogen or disease?

No

8. Did your laboratory develop new vaccines for the designated pathogen or disease?

9. Did your laboratory validate vaccines according to WOAH Standards for the designated pathogen or disease?

TOR4: DIAGNOSTIC TESTING FACILITIES

10. Did your laboratory carry out diagnostic testing for other WOAH Members?

Yes

Name of WOAH Member Country seeking assistance	Date	Which diagnostic test used	No. samples received for provision of diagnostic support	No. samples received for provision of confirmatory diagnoses
FRANCE	2025-10-15	ELISA	10	0
FRANCE	2025-11-15	ELISA, rRT-PCR	80	0
CANADA	2025-12-15	ELISA	0	620

11. Did your laboratory provide expert advice in technical consultancies on the request of an WOAH Member?

Yes

Name of the WOAH Member Country receiving a technical consultancy	Purpose	How the advice was provided
THE NETHERLANDS	Exchanges on immunogenic AMPV proteins	Email
ITALY	Exchanges on AMPV strain detection	Email
CHINA (PEOPLE'S REP. OF)	Exchanges on AMPV strain detection	Email
ITALY	Exchanges on vaccine strains	Email, video-conference
UNITED KINGDOM	Exchanges on MPV genome detection development tool	Email
CANADA	Consultation on an incoming seroprevalence study	Email, video-conference

TOR5: COLLABORATIVE SCIENTIFIC AND TECHNICAL STUDIES

12. Did your laboratory participate in international scientific studies in collaboration with WOAH Members other than the own?

13. In exercising your activities, have you identified any regulatory research needs* relevant for WOAH?

No

TOR6: EPIZOOLOGICAL DATA

14. Did your Laboratory collect epidemiological data relevant to international disease control?

Yes

If the answer is yes, please provide details of the data collected:
Serological data linked with the a collaborative scientific and technical study about seroprevalence in Canada

15. Did your laboratory disseminate epidemiological data that had been processed and analysed?

No

16. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category and list the details in the box)

a) Articles published in peer-reviewed journals:

0

b) International conferences:

0

c) National conferences:

0

d) Other (Provide website address or link to appropriate information):

1
Conference on "Metapneumoviruses in poultry" for the professional diploma of Poultry Farm Advisor training courses, Avipole formation, France

TOR7: SCIENTIFIC AND TECHNICAL TRAINING

17. Did your laboratory provide scientific and technical training to laboratory personnel from other WOAH Members?

No

TOR8: QUALITY ASSURANCE

18. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)	
ISO 17025	see attached file	Compliance certificate ISO 17025 2025.pdf

19. Is your quality management system accredited?

Yes

Test for which your laboratory is accredited	Accreditation body
Avian Influenza Diagnosis	COFRAC

20. Does your laboratory maintain a “biorisk management system” for the pathogen and the disease concerned?

Yes

The laboratory quality management system and procedures comply with nationally applicable regulations and cover biorisk (biosafety and biosecurity) evaluation and management, in line with recommandations of chapter 1.1.4 of OIE Manual

TOR9: SCIENTIFIC MEETINGS

21. Did your laboratory organise scientific meetings related to the pathogen in question on behalf of WOAH?

No

22. Did your laboratory participate in scientific meetings related to the pathogen in question on behalf of WOAH?

No

TOR10: NETWORK WITH WOAH REFERENCE LABORATORIES

23. Did your laboratory exchange information with other WOAH Reference Laboratories designated for the same pathogen or disease?

Not applicable (only WOAH Reference Laboratory designated for the disease

24. Are you a member of a network of WOAH Reference Laboratories designated for the same pathogen?

Not applicable (only WOAH Reference Laboratory designated for the disease

25. Did you organise or participate in inter-laboratory proficiency tests with WOAH Reference Laboratories designated for the same pathogen during the past 2 years?

Not applicable (Only WOAH Reference Laboratory designated for the disease)

not applicable

26. Did your laboratory collaborate with other WOAH Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

Not applicable (only WOAH Reference Laboratory designated for the disease

TOR11: OTHER INTERLABORATORY PROFICIENCY TESTING

27. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than WOAH Reference Laboratories for the same pathogen during the past 2 years?

Yes

Purpose for inter-laboratory test comparisons1	Role of your reference laboratory (organizer/participant)	No. participating laboratories	Name of the test	WOAH Member Countries
antibody detection in serum	Participant	25	ELISA	AUSTRALIA, AUSTRIA, COLOMBIA, FRANCE, GERMANY, HUNGARY, ISRAEL, JORDAN, KAZAKHSTAN, MALAYSIA, NAMIBIA, THE NETHERLANDS, TURKEY, UNITED KINGDOM, UNITED STATES OF AMERICA, ZIMBABWE,

TOR12: EXPERT CONSULTANTS

28. Did your laboratory place expert consultants at the disposal of WOAH?

Yes

Kind of consultancy	Location	Subject (facultative)
Expert advice on questions about "Case definition"	email	Turkey Rhinotracheitis case definition

29. Additional comments regarding your report:

Yes

Human resources issues reported on the two previous years have been progressively solved in 2025, and the AMPV-Turkey rhinotracheitis team has been reconstituted as of end of 2025. We are confident that efforts to stregthen international contacts and interactions initiated in 2025 can be fully emphasized in 2026. The number of international requests for sample submissions remains low, there is an ongoing seroprevalence study with Canada